Search research articles
Contact Us
Filters
Showing results (101-110 of 109) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 109 results.
Immunological Reviews
|
March 1, 1988
The isolation and characterization of a family of serine protease genes expressed in activated cytotoxic T lymphocytes
R C Bleackley, C G Lobe, B Duggan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2003
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial
David B Duggan, Gina R Petroni, Jeffrey L Johnson, et al.
Breast Cancer Research and Treatment
|
February 29, 2008
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)
G G Kimmick, C Cirrincione, D B Duggan, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy
|
August 1, 1992
A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B
D B Duggan, M T Santarelli, K Zamkoff, et al.
Blood
|
August 15, 1993
Phenotypic markers and BCL-1 gene rearrangements in B-cell chronic lymphocytic leukemia: a Cancer and Leukemia Group B study
R A Newman, B Peterson, F R Davey, et al.
Medical and Pediatric Oncology
|
January 1, 1994
Combination trial of subcutaneous recombinant alpha 2 b interferon and oral cyclophosphamide in follicular low-grade non-Hodgkin's lymphoma
H Ozer, J R Anderson, B A Peterson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 14, 2001
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662
D F Hayes, H Yamauchi, G Broadwater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2003
Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140
H L Parnes, C Cirrincione, J Aisner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2003
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
I Craig Henderson, Donald A Berry, George D Demetri, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 109) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 109 results.
Immunological Reviews
|
March 1, 1988
The isolation and characterization of a family of serine protease genes expressed in activated cytotoxic T lymphocytes
R C Bleackley, C G Lobe, B Duggan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2003
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial
David B Duggan, Gina R Petroni, Jeffrey L Johnson, et al.
Breast Cancer Research and Treatment
|
February 29, 2008
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)
G G Kimmick, C Cirrincione, D B Duggan, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy
|
August 1, 1992
A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B
D B Duggan, M T Santarelli, K Zamkoff, et al.
Blood
|
August 15, 1993
Phenotypic markers and BCL-1 gene rearrangements in B-cell chronic lymphocytic leukemia: a Cancer and Leukemia Group B study
R A Newman, B Peterson, F R Davey, et al.
Medical and Pediatric Oncology
|
January 1, 1994
Combination trial of subcutaneous recombinant alpha 2 b interferon and oral cyclophosphamide in follicular low-grade non-Hodgkin's lymphoma
H Ozer, J R Anderson, B A Peterson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 14, 2001
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662
D F Hayes, H Yamauchi, G Broadwater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2003
Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140
H L Parnes, C Cirrincione, J Aisner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2003
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
I Craig Henderson, Donald A Berry, George D Demetri, et al.
Page
of 11